(Q44881822)

7 December 2017

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis (English)

1 reference

relapsing-remitting multiple sclerosis

7 December 2017

0 references

0 references

1 reference

3

1 reference

7 December 2017

A John Petkau

1

1 reference

7 December 2017

Richard A White

2

1 reference

7 December 2017

Anthony T Reder

4

1 reference

7 December 2017

William A Sibley

5

1 reference

7 December 2017

Fred D Lublin

6

1 reference

7 December 2017

Donald W Paty

7

1 reference

7 December 2017

IFNB Multiple Sclerosis Study Group

8

1 reference

7 December 2017

1 April 2004

1 reference

Multiple Sclerosis Journal

7 December 2017

1 reference

7 December 2017

10

1 reference

7 December 2017

2

1 reference

7 December 2017

126-138

1 reference

A novel sensitive and selective bioassay for human type I interferons

7 December 2017

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Correlation of the appearance of anti-interferon antibodies during treatment and dimunition of efficacy: summary of an International Workshop on Anti-Interferon Antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Longitudinal data analysis for discrete and continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

An overview of methods for the analysis of longitudinal data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Regression analysis for correlated data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1004OA

10.1191/1352458504MS1004OA

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference